Tanezumab, identified by the catalog designation 880266-57-9, represents a monoclonal antibody solution demonstrating significant potential in alleviating debilitating osteoarthritis pain. This modified antibody uniquely targets sensory growth factor , reducing its function and thereby diminishing click here discomfort within affected areas . The ongoing data surrounding 880266-57-9 highlights its power to provide substantial suffering alleviation while perhaps avoiding the requirement for opioid analgesics. Further research are actively underway to completely determine its sustained well-being and effectiveness .
Grasping Tanezumab's Function in Discomfort Control: An Immune Protein View
Tanezumab, a novel treatment approach, offers a specific pathway in persistent pain alleviation. As a monoclonal antibody, it selectively targets and inhibits nerve expansion factor (NGF), a critical molecule engaged in nerve ache signaling. Unlike standard narcotic medications, tanezumab’s antibody mechanism allows for a focused targeted action, possibly lessening the chance of some frequent side reactions linked with generalized pain reduction. However, its immunological nature necessitates a detailed assessment of potential immune responses and extended consequences when employed within a complete pain management plan.
Tanezumab Reagent (880266-57-9): Composition, Grade & Applications
The Tanezumab Compound with the identifier 880266-57-9 is a vital component in various biomedical applications, particularly concerning chronic inflammation treatment development. Achieving a high level of quality is paramount; therefore, rigorous assessment protocols are employed to guarantee its appropriateness for specific use. Our creation procedure focuses on prioritizing cleanliness , employing sophisticated separation techniques to remove byproducts. Typical parameters include a >95% purity level as determined by Liquid Chromatography and comprehensive verification for protein integrity. The primary uses revolve around its role as a experimental agent for investigating processes of joint degradation and developing novel medical solutions.
- Research Investigations
- Drug Development
- Mechanism Studies
A Science Of Tanezumab: Exploring the 880266-57-9 Immunoglobulin
Tanezumab, identified by the molecular identifier 880266-57-9, represents a innovative medicinal protein targeting pain-sensing development factor receptor (NGF). The mechanism of effect revolves upon specifically attaching to NGF, as a result inhibiting its function and later communication pathway. Researchers have shown that this biological agent provides promise for reducing severe discomfort, particularly in conditions like arthritic conditions and peripheral back pain. More investigations are underway to fully understand its impact and security characteristics.
Latest Developments in This Investigation: Examining the Its Compound
Current studies surrounding tanezumab, a novel therapeutic compound, are increasingly directed on characterizing the role of the particular reagent, compound 880266-57-9. This identification and detailed evaluation of this molecular entity suggests vital for enhancing tanezumab's efficacy and reducing possible undesirable reactions. Preliminary data reveal that the reagent contributes a key function in the therapy's process of action. More exploration are required to fully clarify the reagent’s influence.
Tanezumab Antibody (880266-57-9): Production, Characteristics, and Potential
The production process of tanezumab, an humanized monoclonal antibody (identified by CAS number 880266-57-9), typically involves mammalian cell culture, often utilizing Chinese hamster ovary cells for high yield. Its primary characteristic is its ability to selectively target and degrade cathepsin-K, an enzyme crucial for bone resorption. This binding mechanism results in a significant reduction in osteoclast activity. The molecule exhibits a defined molecular weight and specific amino acid sequence, allowing for detailed characterization through techniques such as mass spectrometry and protein sequencing. Consequently, tanezumab’s potential lies in treating conditions characterized by excessive bone loss, like osteoarthritis and metastatic bone disease, although clinical development has been complex due to adverse event profiles and ongoing evaluation.}